Unicycive Therapeutics delivers presentations on OLC, UNI-494

Unicycive Therapeutics announced that several presentations were delivered on the Company’s two product candidates, oxylanthanum carbonate, OLC, and UNI-494, at the 61st European Renal Association, ERA, Congress. Title: Enhanced Urinary Phosphorous Reduction: Comparative Study of Oxylanthanum Carbonate and Tenapanor in Rats. Results: OLC demonstrated a significant reduction in urinary phosphate excretion compared to vehicle treated animals which was 3X greater than the reduction in urinary phosphate excretion observed with tenapanor which was not statistically different from vehicle. OLC and tenapanor utilize two different mechanisms of action to manage phosphate levels. Title: Oxylanthanum Carbonate for Hyperphosphatemia in End Stage Kidney Disease. Results: The primary endpoint of the study is tolerability as assessed by the incidence of discontinuations due to treatment-related AEs; the pharmacokinetics of OLC will also be evaluated. Title: Oral Administration of UNI-494 Ameliorates Acute Kidney Injury in a Rat Model of Delayed Graft Function: Results: The study concluded that UNI-494 is a potential candidate for prevention of DGF and other clinical conditions dealt with AKI. Title: UNI-494 Phase I Tolerability and Pharmacokinetics: Trial in Progress. Results: The SAD study was successfully completed, and a dose of 80 mg twice a day was carried over to the MAD study, which is currently ongoing. Results of this study are expected in the second half of 2024.